ORIGINAL RESEARCH article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1611964
This article is part of the Research TopicIntegrative Multi-Omics Approaches for Predicting Immunotherapy Efficacy in Solid TumorsView all 7 articles
Integrated multi-omics analysis reveals the immunotherapeutic significance of tumor cells with high FN1 expression in ovarian cancer
Provisionally accepted
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- 2Dongying People’s Hospital (Dongying Hospital of Shandong Provincial Hospital Group), Dongying, Shandong 257091,, China
- 3China Institute of Sport and Health Science, Beijing Sport University, Beijing, China
- 4College of Traditional Chinese Medicine, Jinan University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Ovarian cancer is a highly lethal gynecological malignancy characterized by significant heterogeneity and immunosuppressive tumor microenvironments, contributing to poor prognosis and therapeutic resistance. This study investigates the immunological and prognostic significance of FN1-expressing tumor cells using integrated multi-omics approaches.The study used GEO database data processed with Seurat and Harmony R. Each cluster had marker genes and cells were tested for preference. Cell stemness was measured using AUCell and CytoTRACE. The gene regulatory network was analyzed using pySCENIC. Molecular signaling exchange study was done with CellChat. And immune infiltration as well as prognostic stratification was performed using bulk analysis. Finally, the identified FN1 targets were validated in conjunction with the spatial transcriptome as well as experimentally.The study highlighted FN1 expression as a key factor in ovarian cancer prognosis and immune resistance. High FN1 tumor cells were linked to poor survival. FN1 knockdown inhibited tumor growth by reducing tumor cells aggregation, invasion, and migration. Our findings suggested that FN1+ tumor cells contributed to immunotherapy resistance, making FN1 a potential biomarker and therapeutic target for improving treatment outcomes in ovarian cancer.Conclusions: A prognostic model created based on FN1 tumor cells provided a new idea for clinical staging of ovarian cancer patients. Meanwhile, this study provided new insights into the heterogeneity of tumor cells and suggested a potential therapeutic target, FN1, which could be helpful for precise immunotherapy of ovarian cancer.
Keywords: FN1 signaling pathway, Prognostic stratification, Spatial transcriptomics, immune infiltration analysis, ovarian cancer
Received: 15 Apr 2025; Accepted: 30 May 2025.
Copyright: © 2025 Zhang, Wu, Zhikai, Nie, Zhao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xinyi Zhang, Clinical Medical College, Southwest Medical University, Luzhou, China
Wei Nie, Dongying People’s Hospital (Dongying Hospital of Shandong Provincial Hospital Group), Dongying, Shandong 257091,, China
Fu Zhao, College of Traditional Chinese Medicine, Jinan University, Guangzhou, China
Shouyan Wang, Dongying People’s Hospital (Dongying Hospital of Shandong Provincial Hospital Group), Dongying, Shandong 257091,, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.